Endometrial Cancer
EORTC-55991 / MaNGO ILIADE-III: Adding Sequential Chemotherapy to Adjuvant Radiotherapy in High-Risk Endometrial Cancer
Sacituzumab Govitecan in Recurrent Endometrial Cancer (NCT04251416)
Fulvestrant + Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer (NCT03643510)
PORTEC-4a: Molecular Profile-Based Adjuvant Treatment for High-Intermediate Risk Endometrial Cancer
AtTEnd: Atezolizumab plus Chemotherapy for Advanced or Recurrent Endometrial Cancer
Trastuzumab in HER2-Positive Uterine Serous Carcinoma (Fader)
GOG 161: Ifosfamide ± Paclitaxel in Advanced Uterine Carcinosarcoma
ASTEC: Pelvic Lymphadenectomy in Endometrial Cancer
LARA: Pembrolizumab plus Lenvatinib in Recurrent Gynaecological Clear Cell Carcinoma
Pembrolizumab plus lenvatinib demonstrated promising anti-tumor activity with an objective response rate of 40% at 24 weeks in patients with recurrent gynaecological clear cell carcinoma.